Puma Biotechnology, Inc.(Nasdaq: PBYI) announced the release of two abstracts on its drug neratinib.
In addition, the Puma Biotechnology papers will be presented at the European Society for Medical Oncology(ESMO) 2017 Congress. It will be held September 8 – 12 in Madrid, Spain.
Furthermore, the abstracts are available to the public online on the ESMO website: www.esmo.org.
Neratinib was approved by the U.S. Food and Drug Administration in July. It is designed for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer. Meanwhile, it is marketed in the United States as NERLYNX™ (neratinib) tablets.
Most noteworthy, research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery. Nevertheless, up to 25% of patients treated with trastuzumab experience recurrence.
